On the heels of a Phase III failure, Spectrum Pharmaceuticals Inc. has announced April 5 that it will buy specialty cancer outfit Allos Therapeutics Inc. The beleaguered biotechs may have found a match that will make the combined company worth more than the sum of its parts.
Spectrum has agreed to pay $1.82 per share, or $206 million, upfront to Allos shareholders, along with a Contingent Value...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?